WST Maintains Rating by Evercore ISI Group -- Price Target Raises to $410
Evercore ISI Group has maintained an "Outperform" rating for West Pharmaceutical Services (WST) and raised its price target from $390.00 to $410.00. The company is considered 1.2% undervalued according to GuruFocus's GF Value™ and holds a strong GF Score™ of 95/100, indicating robust financial health. Although insiders have sold $1.1 million in stock recently, analysts remain confident in WST's growth potential in the medical devices and instruments sector.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DexCom, Inc. (DXCM) is positioned for growth due to the expanding continuous glucose monitoring (CGM) market, strong first-quarter 2026 performance, and a robust international presence. Key drivers include the expansion into the type 2 non-insulin diabetes population, the successful launch of the G7 15-Day system, and significant growth in international markets. However, the company faces risks such as uncertain CMS reimbursement decisions, rising input costs, and potential moderation of U.S. CGM market growth.
Here's Why You Should Retain DexCom Stock in Your Portfolio for Now
DexCom (DXCM) is well-positioned for growth due to the expanding continuous glucose monitoring (CGM) market, strong Q1 2026 performance, and robust international presence. Despite competitive risks and potential delays in CMS reimbursement, the company's G7 15-Day launch and international market strategies are expected to drive customer retention and market share gains. Analysts predict continued positive earnings and revenue trends for DexCom in the coming quarters.
West Pharmaceutical's Premium: Can Biologics Momentum Justify a 49x P/E?
West Pharmaceutical Services (WST) has seen its shares surge over 33% year-to-date, driven by strong demand for high-value components and biologics, pushing its valuation to a demanding 48.64x TTM P/E. Despite robust Q1 2026 results and an upgraded outlook, analysts are divided on whether the premium valuation is sustainable, with some suggesting limited upside and others maintaining "Buy" ratings with increased price targets. The article suggests a cautious investment approach, recommending an entry point if shares pull back and setting a 12-month target of $385.00 while noting that consistent trading below $295.00 would invalidate the investment thesis.
West Pharmaceutical Services (WST) Stock Looks Overvalued Despite Upcoming Q2 Earnings
West Pharmaceutical Services (WST) stock has seen a 65.1% return over the past year, but a new analysis suggests it's overvalued. Trading at 47.6x earnings, significantly higher than the industry average, the company's P/E multiple is estimated to be fair at around 22.4x. Despite optimism around upcoming earnings and the SmartDose 3.5mL transaction, the current price reflects high expectations, suggesting investors are paying a premium for recent momentum.
WST Stock Up Nearly 33% YTD: Will the Uptrend Continue in the Rest of 2026?
West Pharmaceutical Services (WST) stock has seen a significant 32.9% year-to-date increase in 2026, outperforming its industry and the S&P 500. This rally is attributed to strong first-quarter earnings, accelerating demand for high-value injectable drug components, particularly GLP-1 therapies, and growth in its biologics business. Despite competition and potential risks from rising costs and reliance on GLP-1 demand, the company's strategic growth drivers and positive analyst estimates suggest continued upside through 2026.
Ecolab Closes CoolIT Acquisition, Strengthens AI Cooling Portfolio
Ecolab has finalized its acquisition of CoolIT Systems for approximately $4.75 billion, ahead of schedule. This strategic move significantly bolsters Ecolab's footprint in the AI infrastructure market by incorporating CoolIT's direct liquid cooling technologies. The acquisition is expected to drive Ecolab's High-Tech business to $4 billion in annual sales by 2030, enhancing its offerings for semiconductor manufacturing and AI data centers.
Ecolab Closes CoolIT Acquisition, Strengthens AI Cooling Portfolio
Ecolab (ECL) has completed its $4.75 billion acquisition of CoolIT Systems, a direct liquid cooling specialist, strengthening its position in the AI infrastructure market. This acquisition is expected to significantly bolster Ecolab's High-Tech business, with management projecting annual sales of $4 billion by 2030 for the segment. The integration of CoolIT's technology with Ecolab's existing solutions will enable comprehensive offerings for semiconductor manufacturing and AI data centers, supporting long-term growth despite short-term earnings headwinds from acquisition-related costs.
West Pharmaceutical Services Stock 10-Day Winning Spree: Stock Climbs 13%
West Pharmaceutical Services (WST) has experienced a 10-day winning streak, with its stock climbing 13% and its market cap increasing by $3.0 billion. Despite this strong performance, the stock is considered "Relatively Expensive" due to its "Very High valuation," suggesting that while operating performance is strong, the current price may not be an immediate buying opportunity. The article also provides a comparison of WST stock returns against the S&P 500 and highlights the Trefis High Quality Portfolio for outperforming benchmarks.
West Pharmaceutical Services (WST) Is Up 6.7% After 21% Revenue Growth on Drug Delivery Demand
West Pharmaceutical Services (WST) reported a 21% revenue growth, driven by strong demand for its injectable drug delivery systems. The company's investment narrative centers on the continued reliance of injectable therapies on high-value components, with future revenue projected to reach $3.9 billion and earnings $766.2 million by 2029. While the recent sale of SmartDose rights to AbbVie presents a catalyst by reshaping its contract manufacturing mix, investors should also consider potential risks related to execution and pricing pressures.
Revvity Expands Signals AI With Anthropic Claude Integration
Revvity, Inc. announced the integration of its Signals Software business with Anthropic’s Model Context Protocol (MCP) connectors, allowing scientists to access Signals AI and R&D knowledge through Claude, including Claude Science. This expansion aims to enhance how researchers interact with complex R&D data using natural language, supporting data traceability and scientific accuracy. The collaboration is expected to strengthen Revvity's position in the AI-enabled research informatics market, drive wider adoption of Signals Software, and contribute to long-term growth in life sciences.
Join Class Action to Recover Losses from West Pharmaceutical Services, Inc. (WST) – Contact Levi & Korsinsky Before July 7, 2025
Levi & Korsinsky LLP has filed a class action securities lawsuit against West Pharmaceutical Services, Inc. (NYSE: WST) to recover losses for shareholders affected by alleged securities fraud between February 16, 2023, and February 12, 2025. The lawsuit claims that the company made false statements regarding customer demand, its HVP portfolio destocking, and the profit margins of its SmartDose device. Shareholders who suffered losses during this period are encouraged to contact Levi & Korsinsky by July 7, 2025, to learn about their rights to seek a recovery.
Here's Why You Should Retain McKesson Stock in Your Portfolio for Now
McKesson (MCK) is recommended for retention due to robust growth in specialty distribution, oncology services, and biopharma solutions, along with improving earnings and strong specialty pharmaceutical momentum. The company faces potential headwinds from IRA-driven drug pricing pressure, uncertain technology solutions growth, and risks associated with its acquisition-led strategy. Despite these challenges, positive estimate revisions for 2026 and a Zacks Rank #3 (Hold) suggest continued stability.
West completes sale of on-body drug delivery device to AbbVie
West Pharmaceutical Services announced the completion of the sale of its SmartDose 3.5mL on-body delivery system, including manufacturing and supply rights, to AbbVie. The transaction, agreed upon in January, involved a total consideration of $112.5 million. West will continue to develop and manufacture other SmartDose versions.
West Pharmaceutical Services Stock Surges 13%, With A 9-Day Winning Spree
West Pharmaceutical Services (WST) stock has seen a 13% surge over a 9-day winning streak, increasing its market cap by $3.0 billion to $26 billion. Despite this recent strong performance, the stock is considered "Relatively Expensive" due to its "Very High valuation," although its operating performance and financial condition are strong. The article also provides a table comparing WST's returns against the S&P 500 over various periods and highlights the importance of predictive signals for identifying future winners.
Revvity Expands Signals AI With Anthropic Claude Integration
Revvity's Signals Software business has integrated with Anthropic's Model Context Protocol (MCP) connectors, allowing scientists to access Signals AI and R&D knowledge through Claude, including Claude Science. This expansion beyond the Signals One platform enables researchers to combine Claude's reasoning capabilities with Revvity's governed data and scientific context, addressing the challenge of providing AI models with trusted scientific data. The integration aims to drive wider adoption of Signals Software and reinforce Revvity's leadership in AI-enabled research informatics, benefiting from the growing AI in life sciences analytics market.
Revvity Expands Signals AI With Anthropic Claude Integration
Revvity's Signals Software business has integrated with Anthropic's Model Context Protocol (MCP), allowing scientists to access Signals AI and R&D knowledge through Claude. This expansion aims to enhance AI-enabled research informatics by securely connecting Claude's reasoning capabilities with Revvity's governed scientific data. The company's stock, RVTY, saw a 1.4% gain following the announcement, reflecting positive market sentiment for this strategic move into the growing AI in life science analytics market.
KeyBanc Adjusts PT on West Pharmaceutical Services to $390 From $350, Maintains Overweight Rating
KeyBanc has increased its price target for West Pharmaceutical Services (WST) to $390 from $350, while reiterating an "Overweight" rating on the stock. This adjustment reflects a positive outlook for the company from the analytical firm. The article also notes recent company activities, including the sale of SmartDose 3.5mL manufacturing rights and recent executive changes.
West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
West Pharmaceutical Services, Inc. (NYSE: WST) has completed the sale and transfer of the manufacturing and supply rights for its SmartDose® 3.5mL On-Body Delivery System and related facilities, as planned on July 1, 2026. The company will continue to develop and manufacture other SmartDose versions, including the 10mL system for larger volumes. West is a global leader in injectable drug administration solutions, headquartered in Exton, Pennsylvania.
West Pharmaceutical Services, Inc. (WST) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before July 7, 2025
Levi & Korsinsky LLP has filed a class action securities lawsuit against West Pharmaceutical Services, Inc. (WST), seeking to recover losses for shareholders who experienced adverse effects from alleged securities fraud between February 16, 2023, and February 12, 2025. The lawsuit claims that West Pharmaceutical Services made false statements and concealed information regarding customer demand, destocking of its HVP portfolio, and operational inefficiencies with its SmartDose device that negatively impacted profit margins. Investors who suffered losses are urged to contact Levi & Korsinsky before July 7, 2025, to learn about their rights to seek recovery.
Form 4 West Pharmaceutical Services Inc For: 1 July By Investing.com
This article from Investing.com reports the filing of a Form 4 by West Pharmaceutical Services Inc. on July 1st. The filing pertains to West Pharmaceutical Services (WST), which saw a 1.71% increase in its stock value.
West Pharmaceutical (WST) director awarded new phantom stock units and RSUs
West Pharmaceutical Services Inc. director Janet Brutschea Haugen has been awarded 46 new Phantom Stock Units and holds 791 restricted stock units (RSUs) and dividend equivalents. This compensation, which will be settled in stock upon her termination as a director for phantom units and vest at the next annual shareholder meeting for RSUs, increases her total phantom unit balance to 306.678 and reinforces her alignment with shareholder interests. The Form 4 filing details these routine equity-based awards, indicating no open-market stock purchases or sales.
West Pharmaceutical Services stock hits 52-week high at 363.38 USD
West Pharmaceutical Services (WST) stock recently hit a 52-week high of $363.38, reflecting a 64.01% increase over the past year. Despite a high P/E ratio, the company boasts a $25.6 billion market cap, 11% revenue growth, and 33 consecutive years of dividend increases. Recent positive analyst upgrades, a new CEO announcement, and recovery from a cyberattack contribute to its strong market position.
West Pharmaceutical Services (WST) Is Up 6.7% After 21% Revenue Growth on Drug Delivery Demand
West Pharmaceutical Services (WST) reported a 21% revenue growth, driven by strong demand for its advanced drug delivery systems. This performance highlights the company's central role in injectable drug therapies and influences its investment outlook. The article also touches upon a recent asset sale to AbbVie, emphasizing how the company navigates shifting market demands and contract manufacturing transitions.
West Pharmaceutical Services stock hits 52-week high at 363.38 USD
West Pharmaceutical Services (WST) stock has reached a new 52-week high of $363.38, reflecting a 64.01% increase over the past year. The company, with a market cap of $25.6 billion and 11% revenue growth, has raised its dividend for 33 consecutive years. Recent positive developments include an upgrade to Overweight by Barclays with a $400 price target, an Outperform rating from Wolfe Research, a new CEO appointment, and progress in cyberattack recovery efforts.
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day
West Pharmaceutical Services Inc. (WST) shares rose 1.67% to $365.00 on Wednesday, marking its ninth consecutive day of gains. This performance occurred on a down day for the broader market, with both the S&P 500 Index (SPX) and Dow Jones Industrial Average (DJIA) closing lower. The company's stock outperformed its competitors despite the overall market's grim trading session.
West Completes Sale and Transfer of the Manufacturing and Supply Rights for SmartDose® 3.5mL On-Body Delivery System
West Pharmaceutical Services, Inc. announced the completion of the sale and transfer of the manufacturing and supply rights for its SmartDose® 3.5mL On-Body Delivery System and related facilities. The transaction closed on July 1, 2026. West will continue to develop and manufacture other SmartDose versions, including the SmartDose® 10mL system.
NTRA & Aveta Partner to Advance MRD-Guided Trial in Head & Neck Cancer
Natera (NTRA) has partnered with Aveta Biomics to integrate its Signatera test into AVTA 30-01, a global Phase 3 trial for APG-157 in head and neck squamous cell carcinoma. This collaboration aims to assess molecular residual disease (MRD) and treatment response, further validating Signatera's potential in precision oncology. The partnership is expected to strengthen Natera's position and explore more biopharma collaborations for MRD-guided treatments.
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device
Artivion has received FDA premarket approval for its AMDS Hybrid Prosthesis, designed to treat acute DeBakey Type I aortic dissections. This approval removes the previous requirement for institutional review board oversight, which is expected to broaden adoption across U.S. hospitals and capitalize on an estimated $150 million annual market opportunity. The AMDS device, supported by data showing reduced mortality and adverse events, reinforces Artivion's competitive position in the aortic disease market.
Resmed sets Aug. 6 webcast for fiscal Q4 results
Resmed (NYSE: RMD) announced it will release its fourth quarter fiscal year 2026 financial and operational results on Thursday, August 6, 2026, after the NYSE closes. Management will host an earnings webcast at 1:30 p.m. PT / 4:30 p.m. ET, accessible via its investor relations website, with replay options available. The announcement also detailed phone replay access until August 20, 2026.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TransMedics Group, Inc. (TMDX) is positioned for growth due to its innovative Organ Care System (OCS) technology and solid first-quarter 2026 results. Despite a year-to-date stock decline and gross margin pressures, the company's robust pipeline, including next-generation OCS systems and expansion into new organ markets like kidney transplantation, supports its long-term strategy. Analysts maintain a "Hold" rating, while the company continues to invest in expansion and clinical programs.
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day
Shares of West Pharmaceutical Services Inc. (WST) rose 1.22% to $359.00 on Tuesday, marking its eighth consecutive day of gains. The stock's performance outperformed major indices, with the S&P 500 Index (SPX) up 0.79% and the Dow Jones Industrial Average (DJIA) up 0.26%. This strong trading day highlights West Pharmaceutical Services Inc.'s positive market momentum.
Reasons to Retain TransMedics Stock in Your Portfolio for Now
TransMedics Group, Inc. (TMDX) is in a good position for future growth, primarily due to its advanced Organ Care System (OCS) technology and solid first-quarter 2026 results. The company's OCS technology minimizes ischemic injury and improves organ viability, positioning it as a leader in the transplant market. However, TransMedics faces ongoing pressure on its gross margin due to investments in expansion and clinical programs.
West Pharmaceutical Services Inc. stock rises Monday, still underperforms market
West Pharmaceutical Services Inc. (WST) stock increased by 1.09% on Monday, reaching $354.68. Despite this gain, the stock underperformed the broader market, as the S&P 500 Index rose by 1.18% and the Dow Jones Industrial Average gained 0.59%. This marks the seventh consecutive day of gains for West Pharmaceutical Services Inc.
RDNT's Unit DeepHealth Expands AI Breast Suite With FDA-Cleared Tools
RadNet's subsidiary, DeepHealth, recently obtained FDA clearances for two new functionalities within its AI-powered Breast Suite: Breast Arterial Calcification (BAC) Assessment and prior exam integration into ProFound Pro, marketed as Mammo Dx. These additions enhance early disease detection, provide comprehensive patient overviews for radiologists, and are commercially available in the U.S. This expansion strengthens DeepHealth's breast imaging platform, addressing both cancer detection and cardiovascular risk assessment.
West Pharmaceutical Services earnings date approaches, shares backed by analyst interest
West Pharmaceutical Services (WST) is approaching its Q2 2026 earnings release on July 23, 2026, with analysts showing a broadly positive outlook. Approximately 75% of analysts rate the stock as a Buy, reflecting confidence in its long-term demand for medical packaging solutions. Recent analyst upgrades and positive price target revisions, coupled with an 8.6% gain in the last 30 days, precede the upcoming earnings report.
Class Action Lawsuit Alert: Levi & Korsinsky Reminds West Pharmac
Levi & Korsinsky LLP has filed a class action securities lawsuit against West Pharmaceutical Services, Inc. (NYSE: WST) on behalf of investors who suffered losses due to alleged securities fraud between February 16, 2023, and February 12, 2025. The lawsuit claims West Pharmaceutical made materially false and/or misleading statements regarding customer demand, destocking of its HVP portfolio, and the profitability of its SmartDose device. Investors affected during this period are encouraged to contact the firm by the July 7, 2025, deadline to learn about their rights to recovery.
Class Action Lawsuit Filed: West Pharmaceutical Services, Inc. (WST) – Join by July 7, 2025 - Contact Levi & Korsinsky
A class action lawsuit has been filed against West Pharmaceutical Services, Inc. (WST) seeking to recover losses for shareholders affected by alleged securities fraud between February 16, 2023, and February 12, 2025. The lawsuit claims the company made false statements regarding customer demand, HVP portfolio destocking, and the profitability of its SmartDose device. Shareholders who suffered losses can join the lawsuit by July 7, 2025, by contacting Levi & Korsinsky, LLP.
Price to earnings forward of West Pharmaceutical Services, Inc. – NYSE:WST
This article provides access to the forward Price to Earnings (P/E) ratio for West Pharmaceutical Services, Inc. (NYSE: WST) on the TradingView platform. It highlights that the information is available under the Financials section of the company's profile on TradingView. The content itself does not contain the specific P/E value but rather points to its location.
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day
West Pharmaceutical Services Inc. (WST) shares rose 1.24% to $350.85 on Friday, marking its sixth consecutive day of gains. This occurred despite a generally negative trading session where the S&P 500 Index and Dow Jones Industrial Average both saw slight declines. The article highlights WST's strong performance relative to its competitors and the broader market.
West Pharmaceutical Services, Inc. Actuals & Estimates (NYSE:WST)
This article provides an overview of West Pharmaceutical Services, Inc. (NYSE: WST), including its current stock price, market capitalization, historical performance, and analyst forecasts. It also details the company's recent financial results, such as earnings per share and revenue, and provides information on its dividend payments and employee count.
West Pharmaceutical Services Inc. stock underperforms Thursday when compared to competitors despite daily gains
West Pharmaceutical Services Inc. (WST) stock gained 1.81% on Thursday, marking its fifth consecutive day of increases. Despite this daily gain, the stock underperformed compared to its competitors, as indicated by the mixed performance of the broader market with the Dow Jones Industrial Average rising and the S&P 500 Index slightly falling.
AMN Expands Workforce Intelligence Through Brightfield Alliance
AMN Healthcare has partnered with Brightfield to enhance its healthcare workforce intelligence capabilities by integrating Brightfield's third-party Talent Data Exchange with AMN's proprietary analytics. This collaboration aims to provide healthcare organizations with greater market transparency and improved labor planning. The partnership is expected to bolster AMN's technology-enabled solutions, support stronger client engagement, and aid in tackling labor shortages and rising workforce costs within the healthcare sector.
Construction Partners (NASDAQ: ROAD) Stands Out As A Cash-Generating Buy While RTX And WST Disappoint
Construction Partners (NASDAQ: ROAD) is highlighted as a compelling investment due to its strong financial performance, including a 6.7% free cash flow margin and significant revenue and EPS growth. In contrast, Raytheon (NYSE: RTX) and West Pharmaceutical Services (NYSE: WST) are presented as less attractive options, facing concerns about growth deceleration, capital allocation, and margin deterioration, despite having solid free cash flow margins. The article emphasizes Construction Partners' ability to generate and profitably allocate cash, setting it apart from the other two companies.
WST Forecast — Price Target — Prediction for 2027
This article provides a forecast for West Pharmaceutical Services, Inc. (WST) stock, including analyst price targets, historical performance, earnings, and revenue. It highlights that analysts have a maximum price estimate of $400.00 and a minimum of $325.00 for WST. The company's current stock price, market capitalization, and upcoming earnings report are also detailed.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
Ecolab (ECL) is positioned for growth due to its strong global high-tech business, digital platform, and robust product portfolio backed by R&D, as evidenced by its solid first-quarter 2026 results. The company's acquisitions and technology-driven solutions are enhancing customer productivity and sustainability. However, potential gains could be offset by risks related to raw material cost volatility and inflationary pressures.
West Pharmaceutical Services Inc. stock outperforms competitors on strong trading day
West Pharmaceutical Services Inc. (WST) saw its stock advance by 1.20% to $340.41 on Wednesday, extending its winning streak to four consecutive days. This performance stands out despite a mixed trading session for the broader market, where the Dow Jones Industrial Average rose and the S&P 500 Index fell.
Here's Why You Should Retain Ecolab Stock in Your Portfolio Now
Ecolab (ECL) is recommended for retention in portfolios due to its strong product portfolio, robust first-quarter 2026 performance, and continued focus on research and development, particularly within its Global High-Tech business and digital platform. The company's innovative, digitally-enabled solutions and strong Q1 results are positive indicators, although concerns about cost fluctuations in raw materials and supply chains persist.
West Pharmaceutical Services stock hits 52-week high at $338.73
West Pharmaceutical Services (WST) stock has reached a new 52-week high of $338.73, marking a 52.2% increase over the past year. The company, valued at $23.77 billion, trades at a P/E ratio of 44.67, indicating premium valuations in the healthcare equipment sector despite InvestingPro suggesting it may be overvalued. Recent positive developments include an upgrade to Overweight by Barclays, an Outperform rating from Wolfe Research, and the announcement of a new President and CEO, Michel Lagarde, effective August 31, 2026.
WST Stock Price and Chart — NYSE:WST
This page provides an overview of West Pharmaceutical Services, Inc. (WST) stock, including its current price, performance metrics, key financial stats, and company information. It also includes various trading ideas and technical analyses from the TradingView community, along with analyst ratings and ETF holdings.
